Published in Lung Cancer on February 19, 2008
Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis. J Cell Mol Med (2009) 1.62
Target therapy in NSCLC patients: Relevant clinical agents and tumour molecular characterisation. Mol Clin Oncol (2013) 1.13
Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC. J Cell Mol Med (2014) 1.00
Gender difference in bone metastasis of human small cell lung cancer, SBC-5 cells in natural killer-cell depleted severe combined immunodeficient mice. Clin Exp Metastasis (2010) 0.78
Phase II Clinical Trial of Gefitinib for the Treatment of Chemonaïve Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status. Clin Med Insights Oncol (2014) 0.77
Esophageal carcinoma cell line with high EGFR polysomy is responsive to gefitinib. Langenbecks Arch Surg (2014) 0.77
A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov (2011) 3.86
International multicenter tool to predict the risk of nonsentinel node metastases in breast cancer. J Natl Cancer Inst (2012) 2.70
Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer (2005) 2.19
Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J Pathol (2009) 2.17
Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Breast Cancer Res Treat (2010) 2.14
Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance. Oncogene (2002) 2.03
p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis. Cancer Res (2006) 1.92
Circulating autoantibodies to phosphorylated α-enolase are a hallmark of pancreatic cancer. J Proteome Res (2010) 1.81
Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial. J Clin Oncol (2012) 1.55
Stereotactic body radiation therapy for lung metastases. Lung Cancer (2011) 1.52
Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms. Ann Thorac Surg (2009) 1.40
Mammary carcinomas with neuroendocrine features--correct understanding and proper use of the terminology. Histopathology (2015) 1.38
Endothelial cell differentiation of human breast tumour stem/progenitor cells. J Cell Mol Med (2009) 1.30
Neuroendocrine differentiation in breast cancer: established facts and unresolved problems. Semin Diagn Pathol (2010) 1.29
Correlation between NK function and response to trastuzumab in metastatic breast cancer patients. J Transl Med (2008) 1.27
Clinicopathological parameters and outcome of 245 patients operated for oral squamous cell carcinoma. J Craniomaxillofac Surg (2006) 1.27
Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast. J Pathol (2014) 1.19
Formalin fixation at low temperature better preserves nucleic acid integrity. PLoS One (2011) 1.16
HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemo-resistance of invasive micropapillary carcinoma of the breast. BMC Cancer (2012) 1.15
The oxytocin receptor antagonist atosiban inhibits cell growth via a "biased agonist" mechanism. J Biol Chem (2005) 1.11
Epidermal growth factor receptor gene in primary tumor and metastatic sites from non-small cell lung cancer. J Thorac Oncol (2009) 1.10
Radical resection of a giant, invasive and symptomatic malignant Solitary Fibrous Tumour (SFT) of the pleura. Lung Cancer (2008) 1.09
Mixed micropapillary-ductal carcinomas of the breast: a genomic and immunohistochemical analysis of morphologically distinct components. J Pathol (2009) 1.08
SF3B1 mutations constitute a novel therapeutic target in breast cancer. J Pathol (2014) 1.07
Routine assessment of prognostic factors in breast cancer using a multicore tissue microarray procedure. Virchows Arch (2006) 1.07
A rare case of breast cancer showing distinct TTF-1 nuclear expression: small-cell carcinoma or not? Histopathology (2015) 1.07
Variations in sentinel node isolated tumour cells/micrometastasis and non-sentinel node involvement rates according to different interpretations of the TNM definitions. Eur J Cancer (2008) 1.07
Potential plasticity of T regulatory cells in pancreatic carcinoma in relation to disease progression and outcome. Exp Ther Med (2012) 1.04
Supportive care in patients with advanced non-small-cell lung cancer. Br J Cancer (2003) 1.04
Reliability of whole sentinel lymph node analysis by one-step nucleic acid amplification for intraoperative diagnosis of breast cancer metastases. Ann Surg (2012) 1.03
Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer. Am J Clin Oncol (2009) 1.01
Autoantibody signature in human ductal pancreatic adenocarcinoma. J Proteome Res (2007) 1.01
The pathologic complete response open question in primary therapy. J Natl Cancer Inst Monogr (2011) 1.01
Imatinib inhibits in vitro proliferation of cells derived from a pleural solitary fibrous tumor expressing platelet-derived growth factor receptor-beta. Lung Cancer (2008) 1.00
International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). J Natl Cancer Inst Monogr (2011) 1.00
Apocrine carcinoma of the breast: a comprehensive review. Histol Histopathol (2013) 0.99
Isolation and characterization of human breast tumor-derived endothelial cells. Oncol Rep (2006) 0.99
Gene expression profiling in breast cancer: a clinical perspective. Breast (2013) 0.99
Steroid hormone receptor in pleural solitary fibrous tumours and CD34+ progenitor stromal cells. J Pathol (2002) 0.98
Colectomy rate in steroid-refractory colitis initially responsive to cyclosporin: a long-term retrospective cohort study. BMC Gastroenterol (2007) 0.97
Calorie restriction protects against age-related rat aorta sclerosis. FASEB J (2005) 0.96
Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients. Cancer (2011) 0.96
Obstructive colon metastases from lobular breast cancer: report of a case and review of the literature. Tumori (2012) 0.96
Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network. BMC Cancer (2009) 0.96
Utility of flow cytometry immunophenotyping in fine-needle aspirate cytologic diagnosis of non-Hodgkin lymphoma: A series of 252 cases and review of the literature. Appl Immunohistochem Mol Morphol (2010) 0.95
Oxytocin induces proliferation and migration in immortalized human dermal microvascular endothelial cells and human breast tumor-derived endothelial cells. Mol Cancer Res (2006) 0.95
IL-7 up-regulates TNF-alpha-dependent osteoclastogenesis in patients affected by solid tumor. PLoS One (2006) 0.95
HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib. Breast Cancer Res Treat (2010) 0.95
Insulated-tip knife endoscopic mucosal resection of large colorectal polyps unsuitable for standard polypectomy. Am J Gastroenterol (2007) 0.95
Efficacy and skin toxicity management with cetuximab in metastatic colorectal cancer: outcomes from an oncologic/dermatologic cooperation. Clin Colorectal Cancer (2008) 0.94
Teratocarcinoma-derived growth factor-1 is upregulated in aldosterone-producing adenomas and increases aldosterone secretion and inhibits apoptosis in vitro. Hypertension (2010) 0.94
Accuracy of tumour size assessment in the preoperative staging of breast cancer: comparison of digital mammography, tomosynthesis, ultrasound and MRI. Radiol Med (2013) 0.94
Head and neck squamous cell carcinoma: role of the human papillomavirus in tumour progression. New Microbiol (2006) 0.92
Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens. Mol Cancer Ther (2007) 0.91
Role of CD31/platelet endothelial cell adhesion molecule-1 expression in in vitro and in vivo growth and differentiation of human breast cancer cells. Am J Pathol (2003) 0.91
Pilot study to relate clinical outcome in pancreatic carcinoma and angiogenic plasma factors/circulating mature/progenitor endothelial cells: Preliminary results. Cancer Sci (2010) 0.91
Osteonecrosis of the jaw after zoledronic acid and denosumab treatment. J Clin Oncol (2011) 0.90
Comparative evaluation of cancer stem cell markers in normal pancreas and pancreatic ductal adenocarcinoma. Oncol Rep (2011) 0.90
Pro-inflammatory cytokines and oxidative stress/antioxidant parameters characterize the bio-humoral profile of early cachexia in lung cancer patients. Oncol Rep (2007) 0.90
PCR-detectable nonneoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis but rare in subjects treated with chemotherapy. J Clin Oncol (2003) 0.89
Pleomorphism of the nuclear envelope in breast cancer: a new approach to an old problem. J Cell Mol Med (2007) 0.89
Accuracy of mammography, digital breast tomosynthesis, ultrasound and MR imaging in preoperative assessment of breast cancer. Anticancer Res (2014) 0.89
In Situ Hybridization Analysis of miR-146b-5p and miR-21 in Thyroid Nodules: Diagnostic Implications. Endocr Pathol (2015) 0.89
Effect of n-3 fatty acids on patients with advanced lung cancer: a double-blind, placebo-controlled study. Br J Nutr (2011) 0.89
Prevalence of complementary/alternative medicines (CAMs) in a cancer population in northern Italy receiving antineoplastic treatments and relationship with quality of life and psychometric features. Qual Life Res (2010) 0.87
Oxytocin is a growth factor for Kaposi's sarcoma cells: evidence of endocrine-immunological cross-talk. Cancer Res (2002) 0.87
Anti-HER2 treatment and breast cancer: state of the art, recent patents, and new strategies. Recent Pat Anticancer Drug Discov (2009) 0.87
Structural, functional, and tissue distribution analysis of human transferrin receptor-2 by murine monoclonal antibodies and a polyclonal antiserum. Blood (2002) 0.87
Human pancreatic carcinoma cells secrete bioactive interleukin-18 after treatment with 5-fluorouracil: implications for anti-tumor immune response. Cancer Biol Ther (2005) 0.87
Micropapillary ductal carcinoma in situ of the breast: an inter-institutional study. Mod Pathol (2009) 0.87
Oxytocin modulates estrogen receptor alpha expression and function in MCF7 human breast cancer cells. Int J Oncol (2002) 0.87
A case of abdominal sarcoidosis in a patient with acute myeloid leukemia. Case Rep Hematol (2013) 0.86
Cell cycle and viral and immunologic profiles of head and neck squamous cell carcinoma as predictable variables of tumor progression. Head Neck (2009) 0.86
Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study. BMC Cancer (2014) 0.86
Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison. BMC Cancer (2010) 0.86
Interpretation of p16(INK4a) /Ki-67 dual immunostaining for the triage of human papillomavirus-positive women by experts and nonexperts in cervical cytology. Cancer Cytopathol (2014) 0.85
Caveolin-1 expression in lung carcinoma varies according to tumour histotype and is acquired de novo in brain metastases. Histopathology (2009) 0.85
Impact of surgery and chemotherapy on cellular immunity in pancreatic carcinoma patients in view of an integration of standard cancer treatment with immunotherapy. Int J Oncol (2009) 0.85
Critical steps in tissue processing in histopathology. Recent Pat DNA Gene Seq (2012) 0.85
Molecular evidence in support of the neoplastic and precursor nature of microglandular adenosis. Histopathology (2012) 0.85
Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting. Future Oncol (2014) 0.85
Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era. Clin Breast Cancer (2008) 0.85
Intrathoracic splenosis: a case report and an update of invasive and noninvasive diagnostic techniques. J Thorac Cardiovasc Surg (2007) 0.85
Bronchiolar columnar cell dysplasia--genetic analysis of a novel preneoplastic lesion of peripheral lung. Virchows Arch (2003) 0.84